A Phase 2/3 trial conducted by Pfizer and BioNTech revealed that the Covid-19 vaccine was safe and generated a “robust antibody response” in children ages 5 to 11.
CDC Says All Vaccines Offer Strong Resistance to the Virus According to a new report from the Centers for Disease Control and Prevention, two-dose regimens of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations in a real-world evaluation at 21 U.S. hospitals during the period between March 11 and August 15. Vaccine effectiveness against COVID-19 hospitalization for Moderna and Pfizer-BioNTech doses were 93 percent and 88 percent, respectively, whereas the single-dose Janssen vaccine had a lower effectiveness rate at 71 percent. Protection for the Pfizer-BioNTech vaccine declined four months after
Researchers are urging more people of color to participate in clinical trials for a COVID-19 vaccine, but participation numbers so far are low.